Streetbeat News

Earnings

HCP

HashiCorp (NASDAQ:HCP) reported Q4 adjusted earnings of $0.05 per share, surpassing the $0.01 estimate, marking a 171.43% increase from last year's losses. Sales reached $155.78M, exceeding the $149.29M estimate, a 14.72% year-over-year increase.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:04 pm

ROST

Ross Stores projects its Q1 earnings per share (EPS) to be between $1.29 and $1.35, surpassing the estimated $1.27. For fiscal year 2024, the company forecasts EPS to be between $5.64 and $5.89, also exceeding the $5.40 estimate.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:04 pm

SCKT

Socket Mobile (NASDAQ:SCKT) reported Q4 2023 earnings of $0.080 per share, surpassing the $(0.060) estimate by 233.33%. However, their quarterly sales of $4.400M fell short of the $4.910M estimate by 10.39%, marking a 14.91% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:02 pm

ROST

Ross Stores reported Q4 2024 earnings of $1.820 per share, surpassing the $1.650 estimate, with sales of $6.022B also beating the $5.814B estimate.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:02 pm

IMMP

Immutep Limited (NASDAQ:IMMP) reported positive safety and initial efficacy data from the first 90mg dosing of eftilagimod alpha (efti) in combination with paclitaxel in a Phase 2/3 trial for metastatic breast cancer, showing no serious adverse events and a 50% overall response rate. Shares of IMMP soared by 11.90% to $2.63.

Portfolio Pulse from Vandana Singh

March 05, 2024 | 8:57 pm

BAYRY

BAYZF

Bayer AG, under new CEO Bill Anderson, has decided to postpone any plans to split the company into separate units for the next three years, focusing instead on addressing current challenges, boosting performance, and creating strategic flexibility. The company is evaluating the potential separation of its Consumer Health or Crop Science divisions but has ruled out a three-way split. Bayer aims to focus on its pharmaceuticals pipeline, litigation, debt reduction, and implementing a new operating model to improve performance, expecting to cut annual costs by €2 billion from 2026. Fiscal year 2023 saw a decline in Crop Science sales, stable Pharmaceuticals sales, and an increase in Consumer Health sales. Bayer forecasts fiscal year 2024 sales between €47 billion to €49 billion, with adjusted EBITDA of €10.7 billion to €11.3 billion, and core earnings per share of €5.10 to €5.50.

Portfolio Pulse from Vandana Singh

March 05, 2024 | 8:25 pm

BAX

DVA

FMS

NVO

Dialysis provider stocks DaVita Inc (DVA), Fresenius Medical Care AG (FMS), and Baxter International Inc (BAX) traded higher after Novo Nordisk A/S (NVO) announced successful trial results for semaglutide, easing concerns over its impact on the kidney care market. Despite initial fears, the 24% reduction in kidney disease progression and related deaths was at the lower end of expectations, leading to a relief rally in the shares of these companies.

Portfolio Pulse from Vandana Singh

March 05, 2024 | 8:21 pm

AMZN

TGT

WMT

Target (NYSE:TGT) reported better-than-expected holiday quarter results, with revenue and net income surpassing estimates. Shares surged 12% as Target announced a paid membership program to compete with Amazon (NASDAQ:AMZN) and Walmart (NYSE:WMT). The program, launching next month, aims to offer same-day delivery and other benefits for $49 per year. Despite a challenging year with sluggish sales and increased theft, Target is optimistic about its sales recovery through new initiatives.

Portfolio Pulse from Upwallstreet

March 05, 2024 | 8:15 pm

GROV

Grove Collaborative Holdings (NYSE:GROV) is scheduled to release its quarterly earnings report on March 6, 2024, with an anticipated EPS of $-0.23. Investors are hopeful for a beat on this estimate and positive future guidance. Despite past earnings misses and mixed stock performance, with a 7.19% decline over the last year, the company's guidance and actual performance relative to estimates will be key factors influencing the stock price.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 8:03 pm

KLXE

KLX Energy Services Hldgs (NASDAQ:KLXE) is scheduled to release its quarterly earnings report on March 6, 2024, with an estimated EPS of $0.01. Investors are looking for an earnings beat and positive guidance for the next quarter. The company's past earnings performance shows a mixed record of beats and misses, with the share price reacting accordingly. Currently, KLXE shares are trading at $7.83, down 43.11% over the last 52 weeks, indicating a negative sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 8:03 pm